Naiyer Rizvi named CMO of Synthekine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Naiyer Rizvi was named chief medical officer of Synthekine Inc.

Rizvi most recently served as the Price Family Professor of Medicine, director of thoracic oncology and co-director of cancer immunotherapy at Columbia University Medical Center. 

He will lead Synthekine’s efforts in advancing its maturing pipeline through clinical investigation, the company said.

Rizvi’s research into mechanisms of sensitivity and resistance to immunotherapy has laid the foundation to the understanding of clinical responses to immune checkpoint inhibitors. Rizvi conducted clinical studies of novel immunotherapy drugs and immunotherapy combinations, including the landmark study to demonstrate a correlation between mutations and neoantigens with durable benefit to immune-checkpoint blockade. 

His clinical research has helped deliver FDA approvals of several landmark immunotherapies, including nivolumab in squamous lung cancer and pembrolizumab in non-small cell lung cancer. 

He was recently research director of the Price Family Comprehensive Center for Chest Care at New York-Presbyterian Hospital.

Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login